JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.12 -0.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

73.81

Max

75.42

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+38.37% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

74.94

Ankstesnė uždarymo kaina

74.12

Naujienos nuotaikos

By Acuity

15%

85%

26 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-24 00:00; UTC

Uždarbis

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026-04-23 23:47; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026-04-23 23:13; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026-04-23 22:33; UTC

Uždarbis

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026-04-23 22:17; UTC

Uždarbis

PLS Executed Offtake Agreement With Ronbay

2026-04-23 22:17; UTC

Uždarbis

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026-04-23 22:16; UTC

Uždarbis

PLS Commences Commissioning of Midstream Demonstration Plant

2026-04-23 22:15; UTC

Uždarbis

PLS Group Reaffirms FY26 Guidance for All Metrics

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026-04-23 22:13; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026-04-23 22:12; UTC

Uždarbis

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:12; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:11; UTC

Uždarbis

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026-04-23 22:10; UTC

Uždarbis

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026-04-23 22:09; UTC

Uždarbis

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026-04-23 22:08; UTC

Uždarbis

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026-04-23 22:04; UTC

Uždarbis

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026-04-23 21:56; UTC

Rinkos pokalbiai
Uždarbis

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-23 21:27; UTC

Uždarbis

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026-04-23 21:25; UTC

Uždarbis

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026-04-23 21:24; UTC

Uždarbis

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026-04-23 21:24; UTC

Uždarbis

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026-04-23 21:21; UTC

Uždarbis

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026-04-23 21:21; UTC

Uždarbis

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

38.37% į viršų

12 mėnesių prognozė

Vidutinis 103.54 USD  38.37%

Aukščiausias 130 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

13

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

26 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat